These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37491519)

  • 1. Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement.
    Wildes DM; Harvey S; Costigan CS; Sweeney C; Twomey É; Awan A; Gorman KM
    Pediatr Nephrol; 2024 Jan; 39(1):315-324. PubMed ID: 37491519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.
    Pape L; Hartmann H; Bange FC; Suerbaum S; Bueltmann E; Ahlenstiel-Grunow T
    Medicine (Baltimore); 2015 Jun; 94(24):e1000. PubMed ID: 26091445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U; Matar RB; Rotz SJ
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
    Giordano P; Netti GS; Santangelo L; Castellano G; Carbone V; Torres DD; Martino M; Sesta M; Di Cuonzo F; Resta MC; Gaeta A; Milella L; Chironna M; Germinario C; Scavia G; Gesualdo L; Giordano M
    Pediatr Nephrol; 2019 Mar; 34(3):517-527. PubMed ID: 30362078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.
    Garnier A; Brochard K; Kwon T; Sellier-Leclerc AL; Lahoche A; Launay EA; Nobili F; Caillez M; Taque S; Harambat J; Michel-Bourdat G; Guigonis V; Fila M; Cloarec S; Djamal-Dine D; de Parscaux L; Allard L; Salomon R; Ulinski T; Frémeaux-Bacchi V; Morin C; Olivier-Abbal P; Colineaux H; Auriol F; Arnaud C; Kieffer I; Brusq C
    J Am Soc Nephrol; 2023 Sep; 34(9):1561-1573. PubMed ID: 37303085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab in STEC-HUS: need for a proper randomized controlled trial.
    Loos S; Oh J; Kemper MJ
    Pediatr Nephrol; 2018 Aug; 33(8):1277-1281. PubMed ID: 29774464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological involvement in children with hemolytic uremic syndrome.
    Costigan C; Raftery T; Carroll AG; Wildes D; Reynolds C; Cunney R; Dolan N; Drew RJ; Lynch BJ; O'Rourke DJ; Stack M; Sweeney C; Shahwan A; Twomey E; Waldron M; Riordan M; Awan A; Gorman KM
    Eur J Pediatr; 2022 Feb; 181(2):501-512. PubMed ID: 34378062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
    Percheron L; Gramada R; Tellier S; Salomon R; Harambat J; Llanas B; Fila M; Allain-Launay E; Lapeyraque AL; Leroy V; Adra AL; Bérard E; Bourdat-Michel G; Chehade H; Eckart P; Merieau E; Piètrement C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dimeglio C; Garnier A
    Pediatr Nephrol; 2018 Aug; 33(8):1385-1394. PubMed ID: 29572749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
    Monet-Didailler C; Chevallier A; Godron-Dubrasquet A; Allard L; Delmas Y; Contin-Bordes C; Brissaud O; Llanas B; Harambat J
    Nephrol Dial Transplant; 2020 Dec; 35(12):2147-2153. PubMed ID: 31411695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab.
    Delmas Y; Vendrely B; Clouzeau B; Bachir H; Bui HN; Lacraz A; Hélou S; Bordes C; Reffet A; Llanas B; Skopinski S; Rolland P; Gruson D; Combe C
    Nephrol Dial Transplant; 2014 Mar; 29(3):565-72. PubMed ID: 24293658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab for Shiga-toxin-induced hemolytic uremic syndrome in adults with neurological involvement.
    Lee BJ; Arter Z; Doh J; Griffin SP; Vittayawacharin P; Atallah S; Shieh KR; Tran MH; Jodele S; Kongtim P; Ciurea SO
    EJHaem; 2024 Jun; 5(3):548-553. PubMed ID: 38895057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.
    Galvez C; Krall P; Rojas A; Oh J; Cano F
    Pediatr Nephrol; 2023 Apr; 38(4):1195-1203. PubMed ID: 35969277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.
    de Zwart PL; Mueller TF; Spartà G; Luyckx VA
    Pediatr Nephrol; 2024 May; 39(5):1369-1385. PubMed ID: 38057431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.
    Kielstein JT; Beutel G; Fleig S; Steinhoff J; Meyer TN; Hafer C; Kuhlmann U; Bramstedt J; Panzer U; Vischedyk M; Busch V; Ries W; Mitzner S; Mees S; Stracke S; Nürnberger J; Gerke P; Wiesner M; Sucke B; Abu-Tair M; Kribben A; Klause N; Schindler R; Merkel F; Schnatter S; Dorresteijn EM; Samuelsson O; Brunkhorst R;
    Nephrol Dial Transplant; 2012 Oct; 27(10):3807-15. PubMed ID: 23114903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
    Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C
    Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.
    Ağbaş A; Göknar N; Akıncı N; Yıldırım ZY; Taşdemir M; Benzer M; Gökçe İ; Candan C; Küçük N; Uzuner S; Özçelik G; Demirkol D; Sever L; Çalışkan S
    Pediatr Nephrol; 2018 Dec; 33(12):2371-2381. PubMed ID: 30159625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical hemolytic uremic syndrome: a clinical conundrum.
    Bajracharya P; Jain A; Baracco R; Mattoo TK; Kapur G
    Pediatr Nephrol; 2016 Oct; 31(10):1615-24. PubMed ID: 27139899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage.
    Luna M; Kamariski M; Principi I; Bocanegra V; Vallés PG
    Pediatr Nephrol; 2021 Jun; 36(6):1499-1509. PubMed ID: 33205220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outbreak of hemolytic uremic syndrome with unusually severe clinical presentation caused by Shiga toxin-producing Escherichia coli O26:H11 in France.
    Minary K; Tanne C; Kwon T; Faudeux C; Clave S; Langevin L; Pietrement C; Enoch C; Parmentier C; Mariani-Kurkdjian P; Weill FX; Jones G; Djouadi N; Morin D; Fila M
    Arch Pediatr; 2022 Aug; 29(6):448-452. PubMed ID: 35662540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab Use in a Temporarily Dialysis-Dependent Patient With Shiga Toxin-Producing
    Weber B; Chan D; Hammer S
    J Pediatr Pharmacol Ther; 2022; 27(1):90-95. PubMed ID: 35002565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.